The most powerful laser in the US recently produced 2 quadrillion watts of power
The University of Michigan has announced that its Zettawatt-Equivalent Ultrashort pulse laser System (ZEUS) produced 2 petawatts, or 2 quadrillion watts of power during its first experiment. That's more than '100 times the global electricity power output,' according to the university, but don't expect it to be harnessed to recreate the Death Star. Those intensely powerful blasts last just 25 quintillionths of a second long, and will be used for experiments in various areas of research including medicine, quantum physics, and materials science.
Funded by the US National Science Foundation, ZEUS cost $16 million to build and includes components like 7-inch sapphire crystals infused with titanium atoms that took over four years to manufacture. 'The size of the titanium sapphire crystal we have, there are only a few in the world,' says ZEUS' project manager, Franko Bayer.
Operating ZEUS isn't as easy as pressing a button on a handheld laser pointer. The power of an initial infrared pulse from a laser is increased using pump lasers that increase its energy. The power is gradually increased through four rounds of these pump lasers, but to ensure the pulse 'doesn't get so intense that it starts tearing the air apart,' it passes through optical devices called diffraction gratings that stretch it out.
The pulse ends up being 12 inches across and a few feet long, but eventually it enters vacuum chambers where additional gratings flatten it down to just 0.8 microns wide so its maximum power intensity can be delivered to experiments.
The first experiment, conducted by Franklin Dollar, a professor of physics and astronomy at the University of California, Irvine, targeted the laser pulse at a cell containing helium. The collision 'produces plasma, ripping electrons off the atoms so that the gas becomes a soup of free electrons and positively charged ions. Those electrons get accelerated behind the laser pulse-like wakesurfers close behind a speedboat, a phenomenon called wakefield acceleration.'
The experiment is designed to eventually produce electron beams that are as powerful as those created by particle accelerators but without the need for expensive hardware installations that are often hundreds of meters in length.
Housed in a facility the size of a school gymnasium at the university's Gérard Mourou Center for Ultrafast Optical Science, ZEUS is the successor to the center's HERCULES laser that reached a maximum power output of 300 terawatts in 2007. First announced in 2022, ZEUS' current power output is roughly double the peak power of other lasers in the US, and it's designed to eventually deliver up to 3 petawatts.
But while ZEUS is the most powerful laser in the US, it's still less powerful than the laser at the European ELI-NP laboratory in Măgurele, Romania that peaks at 10 petawatts of power.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Associated Press
an hour ago
- Associated Press
BioAegis Therapeutics Announces US Navy Contract to Support Phase 2 Study of Recombinant Human Gelsolin, for Inflammasome-Driven Decompression Sickness (DCS)
NORTH BRUNSWICK, N.J., June 10, 2025 (GLOBE NEWSWIRE) -- BioAegis Therapeutics, a pioneering biotech company at the forefront of innovative therapies for acute and chronic inflammatory diseases, announces that it will conduct a Phase 2 study of rhu-pGSN for decompression sickness (DCS) under a contract awarded by the U.S. Navy's Office of Naval Research to the University of Maryland School of Medicine (UMSOM). This work is the culmination of an extended collaboration with Dr. Stephen Thom, Professor of Emergency Medicine at UMSOM. The Company's portfolio is built around gelsolin, a highly conserved and critical immune regulatory protein which rebalances dysfunctional inflammation without suppressing immune function. Phase 2 Clinical Trial of Rhu-pGSN The study, 'Rhu-pGSN to Mitigate Proinflammatory Responses to Decompression in Healthy SCUBA Divers,' NCT06216366 is being conducted under a contract with the Office of Naval Research with the University of Maryland. It will investigate the use of rhu-pGSN as a pre- or post-exposure intervention in healthy trained SCUBA divers exposed to controlled hyperbaric conditions. The study is designed to assess the impact of rhu-pGSN on key inflammatory responses and microparticle production associated with decompression. Decompression sickness occurs when inert gas bubbles form in the bloodstream and tissues due to rapid pressure changes, triggering an inflammatory cascade. Previous studies have shown that individuals with DCS exhibit depleted levels of plasma gelsolin and elevated levels of microparticles that contain inflammatory cytokines. In animal models, supplementation with rhu-pGSN both prevented and mitigated DCS-related complications. This randomized, double-blind, placebo-controlled study will enroll healthy trained SCUBA divers at a single site and expose them to a standardized hyperbaric protocol (30 meters of seawater for 35 minutes). Participants will be randomized into three groups to receive either pre-exposure or post-exposure rhu-pGSN, or placebo. The study will assess a broad range of outcomes including plasma gelsolin levels, inflammatory markers like IL-1β, gas bubble formation, and well-being metrics. Dr. Thom states, 'If successful, this study could transform the way we manage decompression sickness by providing a portable, field-deployable treatment option. Reducing our reliance on hyperbaric chambers would greatly expand our ability to treat DCS in remote or operational environments, improving outcomes and readiness, a key goal for the Navy.' BioAegis and University of Maryland are co-applicants on a patent filing listing Dr. Thom as an inventor. Gelsolin: A Multitasking Protein for Complex Inflammatory Conditions Rhu-pGSN holds immense promise as a therapeutic intervention for serious acute and chronic conditions due to its multifaceted mechanism of action. In critical illness, gelsolin levels collapse, causing adverse outcomes. Supplementing gelsolin addresses this deficit directly, restoring immune balance while preserving host defense and rhu-pGSN has been shown in animal studies to: Supplementation with the recombinant gelsolin protein holds promise to address the overzealous inflammatory response associated many inflammatory diseases without suppressing immune function. About BioAegis BioAegis Therapeutics Inc. is a NJ-based clinical-stage private company whose mission is to capitalize on a key regulatory component of the body's immune system, plasma gelsolin, to prevent adverse outcomes in diseases driven by inflammation. BioAegis has the exclusive license to broad, worldwide intellectual property through Harvard-Brigham and Women's Hospital. It holds over 40 patents issued for coverage of inflammatory disease, infection, renal failure, neurologic disease, and frailty. BioAegis will also have U.S. biologics exclusivity and has recently filed new IP in areas of unmet need. BioAegis' lead product, rhu-pGSN, is currently being studied in a 600-patient global Phase 2 trial for patients with moderate to severe Acute Respiratory Distress Syndrome (ARDS). This project has been supported in whole or in part with federal funds from the U.S. Department of Health and Human Services; Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority (BARDA), under contract number 75A50123C00067. NCT05947955 Investor Inquiries: Steven Cordovano 203-952-6373 [email protected] Media Inquiries: Christine Lagana [email protected]
Health Line
an hour ago
- Health Line
Primary Progressive MS: Myths vs. Facts
Misconceptions about primary progressive multiple sclerosis (PPMS) are common, especially since the condition can look different for everyone. Knowing what's true (and what's not) can help you feel more informed and empowered. Primary progressive multiple sclerosis (PPMS) is a complex condition that looks different from person to person. Symptoms, experiences, and rates of progression can vary widely. Because PPMS isn't as well-known as other types of multiple sclerosis (MS), myths and misconceptions often fill the gaps. That can make it harder to find trustworthy answers when you're trying to learn more about the condition. Here, we break down some of the most common myths about PPMS and share the facts behind them. Myth#1: There will never be a cure for PPMS Fact: While there's no cure yet, treatment options are expanding, and research is ongoing. In 2017, the Food and Drug Administration (FDA) approved Ocrevus (ocrelizumab) as the first disease-modifying therapy (DMT) for PPMS. In 2024, a new formulation called ocrelizumab and hyaluronidase-ocsq (Ocrevus Zunovo), a subcutaneous injection administered twice a year, was approved. This new injection offers a quicker, approximately 10-minute administration alternative to the traditional intravenous infusion. Ocrevus and Ocrevus Zunovo are currently the only FDA-approved DMTs for PPMS. However, researchers are actively exploring new therapies. For instance, tolebrutinib, a Bruton's tyrosine kinase (BTK) inhibitor, is undergoing phase 3 trials to assess its potential in slowing PPMS progression. Additionally, scientists are investigating treatments aimed at repairing myelin, the protective sheath around nerves damaged in MS. One such study involves combining metformin, a common diabetes medication, with clemastine, an antihistamine, to promote myelin repair. Myelin repair is important because it may help restore nerve function and slow disease progression. Although a cure for PPMS has yet to be found, these developments reflect a growing commitment to improving treatment options and outcomes. Myth: PPMS primarily occurs in females Fact: PPMS affects people of all sexes at the same rate. While relapsing-remitting multiple sclerosis (RRMS) is more common in people assigned female at birth (AFAB), affecting them two to three times more often than those assigned male at birth (AMAB), PPMS affects AFABs and AMABs in roughly equal numbers. It's important not to assume the type of MS based solely on sex. Regardless of gender, if you experience symptoms suggestive of MS, consult a healthcare professional for an accurate diagnosis. Myth: PPMS is an older person's disease Fact: PPMS typically begins in mid-adulthood, not old age. While PPMS tends to have a later onset than other forms of MS, it doesn't primarily affect older adults. On average, people with PPMS start experiencing symptoms around the age of 40. Myth: A PPMS diagnosis means you'll be disabled Fact: Disability progression in PPMS varies widely, and many people maintain mobility and independence for years. PPMS can lead to physical disability, but how quickly or whether it develops looks different for everyone. Some people notice gradual changes, while others may stay stable for long stretches of time. Not everyone will need mobility aids like canes or wheelchairs, especially early on. A 2022 study found that about 10% of people with MS experience severe disability within 5 years of diagnosis. That number rises to 25% within 10 years and then increases to 50% after 18 years. Still, this doesn't mean you should expect disability after receiving a PPMS diagnosis. The location of lesions, your overall health, and how early you begin treatment can all play a role in how the condition progresses. Working with your doctor on a treatment plan that includes physical or occupational therapy and regular movement can help you stay active and independent for longer. Myth: Having PPMS means you have to quit your job Fact: Many people with PPMS continue working, sometimes with a few adjustments. A PPMS diagnosis doesn't automatically mean you need to stop working. While symptoms like fatigue, changes in memory or thinking, or mobility issues can make certain jobs more challenging, many people with PPMS continue in full- or part-time work, especially in the early stages. Everyone's experience with PPMS is different, so your ability to work will depend on your specific symptoms and the demands of your job. If you're facing obstacles, workplace accommodations, like flexible hours, assistive devices, or ergonomic adjustments, may help you stay on the job. A conversation with your doctor or a vocational (work) counselor who understands chronic conditions can also help you explore options that support your health and independence. Myth: No medications help PPMS, so you should investigate natural remedies Fact: There are FDA-approved medications that can help slow the progression of PPMS, including ocrelizumab. While some natural remedies might offer symptom relief, they aren't always safe or proven to be effective. For years, there were no FDA-approved treatments for PPMS. That changed in 2017 when Ocrevus (ocrelizumab) became the first medication approved specifically for PPMS. In a study of 732 people with PPMS, those who received Ocrevus experienced a slower rate of disability progression compared to those who received a placebo. It remains the only approved disease-modifying therapy for this form of MS. Doctors may also prescribe medications to manage specific symptoms, such as antidepressants for mood changes or muscle relaxants for spasms. Some people turn to natural remedies like herbal supplements, acupuncture, or cannabis. Research into these options is ongoing, but so far, there's no strong evidence that they're safe or effective for treating MS symptoms. Some supplements can even interact with prescription drugs. If you're considering natural treatments, talk with your doctor first to avoid potential side effects or interactions. Myth: PPMS is ultimately an isolating disease — no one will understand what you're going through Fact: You're not alone, and you don't have to go through it alone either. While PPMS can feel isolating at times, many others are navigating similar challenges. It's estimated that nearly 1 million people in the United States are living with MS, and about 10% to 15% of them have PPMS. Thanks to growing awareness and advocacy, there are now more resources and support networks than ever. Support groups, both in-person and online, offer a space to connect with others who understand what you're going through. If group support isn't for you, that's OK too. Talking with a trusted friend, loved one, or therapist can still help ease feelings of isolation and improve emotional well-being. What matters most is finding a form of support that feels right for you. Myth: PPMS is deadly Fact: PPMS is a lifelong condition, but it's rarely fatal. The progressive nature of PPMS and the fact that there's no cure can understandably lead to fears about long-term outcomes. But while PPMS can affect mobility, thinking, and daily functioning, it's not considered a life threatening illness. Most people with MS who don't have severe disabilities can expect to live another 30 to 35 years after diagnosis. Recent research has shown that even after significant disease progression, many people continue to live for years. For example, after someone loses the ability to walk independently, on average, at around age 51, life expectancy is about 13 more years. Advances in treatment, early intervention, and lifestyle changes can help manage symptoms, reduce complications, and support overall health. Taking care of your physical and emotional well-being through exercise, a balanced diet, regular checkups, and support can make a big difference in quality of life. It's important to note that with ongoing advances in treatment, the outlook for people with PPMS continues to improve. Current data on disability and life expectancy may not reflect what's possible in the future. Takeaway Misconceptions about primary progressive multiple sclerosis (PPMS) can add confusion and fear to an already complex condition. However, the reality is that PPMS doesn't always follow the path people expect. From treatment options to life expectancy, the facts paint a more hopeful and nuanced picture. While every experience with PPMS is different, understanding the reality behind the myths can help you make informed choices, find support, and feel more in control of your journey.
New York Times
an hour ago
- New York Times
Democrats Grill N.I.H. Leader on Cuts: Who Is Calling the Shots?
As the Trump administration clamped down on the country's medical research funding apparatus in recent months, scientists and administrators at the National Institutes of Health often privately wondered how much autonomy the agency's director, Dr. Jay Bhattacharya, had. After all, the Department of Government Efficiency, Elon Musk's signature cost-cutting project, helped drive decisions to cancel or delay research grants. Other projects fell victim to President Trump's face-off with universities over antisemitism. But given an opportunity before a Senate panel on Tuesday to dispel suspicions about who wields influence at the N.I.H., Dr. Bhattacharya did little to claim ownership of perhaps the rockiest period in the agency's many decades of funding research institutions. Decisions to freeze grant payments to Northwestern University 'happened before I got into office,' Dr. Bhattacharya told the panel, members of the Senate Appropriations Committee. He repeatedly said a proposal to shrink the N.I.H. budget by $18 billion — nearly 40 percent — was 'a collaboration between Congress and the administration' and declined to talk in detail about how the cuts would affect the agency. And pressed on an effort to curtail funding to universities for research overhead expenses — a cost-cutting move that is baked into the administration's 2026 budget proposal — Dr. Bhattacharya said, 'I don't want to get into that,' citing ongoing litigation. Several Democrats on the committee said they were confused about who was pulling the strings at the agency. Want all of The Times? Subscribe.
